Heidi Kunz - Avanos Medical Independent Director
| AVNS Stock | USD 14.77 0.05 0.34% |
Director
Ms. Heidi K. Kunz serves as Independent Director of the Company. Ms. Kunz is the Chairperson of the Audit Committee. Ms. Kunz retired as the Executive Vice President and Chief Financial Officer of Blue Shield of California, a notforprofit health plan provider, where she served from 2003 to 2012. Prior to that time, she served as the Executive Vice President and Chief Financial Officer of Gap, Inc., a multinational clothing and accessories retailer, from 1999 until 2003. Ms. Kunz also serves as a director of Agilent Technologies, Inc., a public research development and manufacturing company, and as a director of Financial Engines, Inc., an investment advisement company. Ms. Kunz was selected to serve as a member of our Board of Directors due to her executive leadership experience as a chief financial officer, financial literacy and experience in finance and accounting, knowledge of, and experience in, the healthcare industry, international experience and governance and public company board experience. since 2014.
| Age | 66 |
| Tenure | 11 years |
| Address | 5405 Windward Parkway, Alpharetta, GA, United States, 30004 |
| Phone | 844 428 2667 |
| Web | https://avanos.com |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0197 % which means that it generated a profit of $0.0197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3742) %, meaning that it created substantial loss on money invested by shareholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.64 in 2025. Return On Capital Employed is likely to gain to -0.38 in 2025. At this time, Avanos Medical's Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 446.4 M in 2025, whereas Other Assets are likely to drop slightly above 24.3 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Juan Quiros | Establishment Labs Holdings | 52 | |
| Elizabeth Weatherman | Nevro Corp | 60 | |
| Susan Siegel | Nevro Corp | 60 | |
| Michael DeMane | Nevro Corp | 63 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Kristina Wright | Paragon 28 | 47 | |
| David Bronson | CONMED | 67 | |
| Shawn McCormick | Nevro Corp | 56 | |
| William Summers | Integer Holdings Corp | 70 | |
| Jeffrey Burbank | Artivion | 58 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Martha Aronson | CONMED | 53 | |
| John Workman | CONMED | 69 | |
| Cheryl Blanchard | Anika Therapeutics | 61 | |
| Kevin OBoyle | Nevro Corp | 62 | |
| Charles Farkas | CONMED | 68 | |
| Brad Vale | Nevro Corp | 67 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cato, Vice Resources | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| Chip Zimliki, Senior Affairs | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sigfrido Delgado, Senior Operations | ||
| Jonathan Turner, VP Officer | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary | ||
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| Warren Machan, Interim Officer | ||
| Scott Galovan, Senior Development | ||
| Michael CPA, Senior CEO | ||
| Katrine Kubis, Vice Relations | ||
| Sudhakar Varshney, Senior Procurement | ||
| John Byrnes, Independent Director | ||
| Maria Sainz, Independent Director | ||
| Siobhan Smyth, VP Officer | ||
| Vinny Sastri, Senior Quality | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 | ||||
| Profit Margin | (0.57) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 735.53 M | ||||
| Shares Outstanding | 46 M | ||||
| Shares Owned By Insiders | 3.22 % | ||||
| Shares Owned By Institutions | 95.94 % | ||||
| Number Of Shares Shorted | 888.74 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.